Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage
Oncology Leader Liz Barrett Joins UroGen As CEO As It Heads Towards Commercial Stage
$131.00
There is new leadership at UroGen Pharma, Ltd., as Novartis AG Oncology’s former Oncology CEO takes the helm. Scrip sat down to talk to Liz Barrett about her plans as CEO of UroGen, including assuming the tasks of ushering the company’s lead asset through the FDA approval and launch processes.
Publisher: Scrip
- Description
In Scrip’s interview with newly-named UroGen Pharma, Ltd. CEO, Liz Barrett, she discusses her decision to leave the top oncology post at Novartis AG to lead UroGen, her plans to see UroGen’s lead asset through the FDA approval and launch processes, and her short- and long-term business development plans for the organization. Tap into Scrip’s insightful interview with this key industry leader for insights into the future of UroGen and its urothelial cancer drug, UGN-101.
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
J.P. Morgan Notebook Day 2: Biogen, GSK, Bluebird, Roche, Amgen, Biohaven And... 
Sign up to the